Drug Trial Radar · NCT07282873
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
219
Planned (sponsor's estimate)
Start
Jan 1, 2026
Primary completion
Jan 2028
Study completion Jun 2029
Sponsor
- Lead sponsor
- TYK Medicines, IncIndustry
- Sponsor type
- Industry
- First posted
- Dec 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of the TEAD inhibitor TYK-01054 capsules in patients with locally advanced or metastatic advanced solid tumors
Conditions
- Solid Tumor Malignancies
- Malignant Mesothelioma (MM)
Interventions
TYK-01054Drug
TKY-01054 will be administered orally at a starting dose of 25 mg in 21-day cycles. If well tolerated, dose expansion will proceed in the recommended dose for expansion (RDE) and RDE-1 until the recommended Phase II dose (RP2D) is determined.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting ToxicityTime frame: Up to approximately 28 days
- Maximum tolerated dose(MTD)Time frame: Through the Dose Escalation phase, approximately 12 months
- Number of participants who experience one or more adverse events (AEs)Time frame: From Baseline up to 28 days after the end of the treatment
- Recommended Dose for Expansion(RDE)Time frame: Through the Dose Escalation Phase, approximately 24 months
- Recommended Phase 2 Dose(RP2D)Time frame: Within 28 days of the last patient dosed in the Dose Optimization stage
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.